News - Oncology, Anti-virals


Current filters:


Popular Filters

1 to 25 of 28 results

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA


Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera


In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation


The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products


Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Catalyst-rich period ahead for key trial results from BioLineRx


Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…


Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy


US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

Valneva enters deals with Delta-Vir


Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…


Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine


US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

Generex highlights pipeline potential of Antigen Express subsidiary


Canada-based Generex Biotechnology (OTC Bulletin Board: GNBT) last week provided an overview of the current…

AE37Anti-viralsAntigen ExpressBiotechnologyGenerex BiotechnologyOncologyPharmaceuticalResearchVaccines

Cancer drug shows promise in eradicating latent HIV infection


Breakthrough drugs have made it possible for people to live with HIV longer than ever before, but more…


HIV drug nelfinavir shows efficacy in mouse models of HER2+ breast cancer


The HIV protease inhibitor nelfinavir, marketed by Swiss drug major Roche as Viracept, can be used to…


Arrowhead Research Corp improving focus, say Edison analysts


Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

News briefs: Genmab/GSK, Gilead and Mylan


Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

Alkermes pulls MAA for Megestrol product


The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker…


RusNano to start production of vaccines and organogels


Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

1 to 25 of 28 results

Back to top